These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 4070293)
1. The role of voluntary disease organizations in research and development of orphan drugs. Horansky R Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293 [No Abstract] [Full Text] [Related]
2. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
3. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
5. The National Cancer Institute's Drug Development Program. Schepartz SA Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301 [No Abstract] [Full Text] [Related]
6. The design and development of therapeutic agents for neuromuscular diseases. Lewis NJ Prog Clin Biol Res; 1985; 197():105-10. PubMed ID: 4070284 [No Abstract] [Full Text] [Related]
7. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
8. Understanding orphan drug regulations: an EU and U.S. comparative analysis. Grienenberger A J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604 [TBL] [Abstract][Full Text] [Related]
9. The Orphan Products Board of the Department of Health & Human Services. Crooks GM Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294 [No Abstract] [Full Text] [Related]
10. Orphan drug development in the United States. Groft SC CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306 [TBL] [Abstract][Full Text] [Related]
11. Trends in the support of cancer research in the United States. Endicott KM Proc Can Cancer Conf; 1969; 8():1-8. PubMed ID: 4893427 [No Abstract] [Full Text] [Related]
12. The Antiepileptic Drug Development Program: an example of government-industry collaboration. White BG Prog Clin Biol Res; 1985; 197():83-93. PubMed ID: 4070302 [TBL] [Abstract][Full Text] [Related]
13. Comparability of the American Cancer Society and National Institutes of Health peer review systems. Vivona S; Do van Quy D Cancer Res; 1973 Apr; 33(4):919. PubMed ID: 4739656 [No Abstract] [Full Text] [Related]
15. The Orphan Drug Act and the Federal Government's Orphan Products Development Program. Finkel MJ Public Health Rep; 1984; 99(3):313-6. PubMed ID: 6429731 [TBL] [Abstract][Full Text] [Related]
16. Generic Pharmaceutical Industry Association Orphan Drug Institute. Haddad W Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298 [No Abstract] [Full Text] [Related]
18. Stats and facts. Increasing U.S. health research expenditures. Manag Care Interface; 2001 Oct; 14(10):34-5. PubMed ID: 11688091 [No Abstract] [Full Text] [Related]
19. National Institute of Allergy and Infectious Diseases Challenge Grants designed to spark development of drugs to combat infectious diseases. SoRelle R Circulation; 2000 Oct; 102(15):E9030-1. PubMed ID: 11183866 [No Abstract] [Full Text] [Related]
20. Are orphan product program funds underused by nuclear medicine researchers? Harby K J Nucl Med; 1988 Jun; 29(6):1011-2. PubMed ID: 3373310 [No Abstract] [Full Text] [Related] [Next] [New Search]